PT2855449T - Derivados da sulfonilpiperidina e sua utilização para o tratamento das doenças mediadas por procineticina - Google Patents

Derivados da sulfonilpiperidina e sua utilização para o tratamento das doenças mediadas por procineticina

Info

Publication number
PT2855449T
PT2855449T PT137282380T PT13728238T PT2855449T PT 2855449 T PT2855449 T PT 2855449T PT 137282380 T PT137282380 T PT 137282380T PT 13728238 T PT13728238 T PT 13728238T PT 2855449 T PT2855449 T PT 2855449T
Authority
PT
Portugal
Prior art keywords
prokineticin
treating
mediated diseases
piperidine derivatives
sulfonyl
Prior art date
Application number
PT137282380T
Other languages
English (en)
Inventor
Carroll Colm
Goldby Anne
Teall Martin
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT2855449T publication Critical patent/PT2855449T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT137282380T 2012-05-30 2013-05-29 Derivados da sulfonilpiperidina e sua utilização para o tratamento das doenças mediadas por procineticina PT2855449T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201209587A GB201209587D0 (en) 2012-05-30 2012-05-30 Therapeutic compounds

Publications (1)

Publication Number Publication Date
PT2855449T true PT2855449T (pt) 2018-06-08

Family

ID=46546171

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137282380T PT2855449T (pt) 2012-05-30 2013-05-29 Derivados da sulfonilpiperidina e sua utilização para o tratamento das doenças mediadas por procineticina

Country Status (24)

Country Link
US (6) US20130324576A1 (pt)
EP (1) EP2855449B1 (pt)
JP (1) JP6177896B2 (pt)
CN (1) CN104520292B (pt)
AR (1) AR091208A1 (pt)
CA (1) CA2873850C (pt)
CY (1) CY1120420T1 (pt)
DK (1) DK2855449T3 (pt)
ES (1) ES2671629T3 (pt)
GB (1) GB201209587D0 (pt)
HK (1) HK1208675A1 (pt)
HR (1) HRP20180729T1 (pt)
HU (1) HUE037673T2 (pt)
LT (1) LT2855449T (pt)
ME (1) ME03078B (pt)
NO (1) NO2855449T3 (pt)
PL (1) PL2855449T3 (pt)
PT (1) PT2855449T (pt)
RS (1) RS57329B1 (pt)
SI (1) SI2855449T1 (pt)
TR (1) TR201807666T4 (pt)
TW (1) TWI612041B (pt)
UY (1) UY34835A (pt)
WO (1) WO2013179024A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
EP3010900B1 (en) * 2013-06-21 2018-01-03 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
GB201420095D0 (en) * 2014-11-12 2014-12-24 Takeda Pharmaceutical New use
CN106699635B (zh) * 2015-11-12 2019-10-22 北京福元医药股份有限公司 一种制备Delamanid中间体的方法
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
JP7269943B2 (ja) 2018-01-08 2023-05-09 エフ. ホフマン-ラ ロシュ アーゲー Magl阻害剤としてのオクタヒドロピリド[1,2-アルファ]ピラジン
SI3768684T1 (sl) 2018-03-22 2023-06-30 F. Hoffmann - La Roche Ag Zaviralci oksazin monoacilglicerol lipaze (MAGL)
BR112021002298A2 (pt) 2018-08-13 2021-05-04 F. Hoffmann-La Roche Ag compostos heterocíclicos como inibidores da monoacilglicerol lipase
JP2022548028A (ja) 2019-09-12 2022-11-16 エフ.ホフマン-ラ ロシュ アーゲー Magl阻害剤としての4,4a,5,7,8,8a-ヘキサピリド[4,3-b][1,4]オキサジン-3-オン化合物
CN115989228A (zh) 2020-09-03 2023-04-18 豪夫迈·罗氏有限公司 杂环化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006098A1 (en) 1994-08-24 1996-02-29 Astra Aktiebolag Spiro-azabicyclic compounds useful in therapy
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMIN DERIVATIVES
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
EP1302463A1 (en) 2000-07-18 2003-04-16 Yamanouchi Pharmaceutical Co. Ltd. Medicine comprising dicyanopyridine derivative
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
SI1395567T1 (sl) 2001-05-18 2009-04-30 Astrazeneca Ab 4-(fenil-piperazinil-metil)benzamidni derivati in njihova uporaba za zdravljenje bolečine, tesnobe ali gastrointestinalnih motenj
CA2455341A1 (en) 2001-06-01 2002-12-05 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
EP1676844A1 (en) * 2004-12-28 2006-07-05 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
NZ561993A (en) 2002-04-18 2008-09-26 Astrazeneca Ab Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors
BR0309343A (pt) 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
NZ535978A (en) 2002-04-18 2007-10-26 Astrazeneca Ab Novel spiroazabicyclic heterocyclic amines useful as nicotinic acetylcholine receptor agonists
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
US8580782B2 (en) * 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
BR0315166A (pt) 2002-10-11 2005-08-16 Astrazeneca Ab Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
BR0316164A (pt) 2002-11-12 2005-09-27 Pfizer Prod Inc Derivados de quinolina
JP2006518368A (ja) 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのn−ヘテロシクリル置換アミノチアゾール誘導体
EP1657240A4 (en) 2003-08-18 2009-04-08 Fujifilm Finechemicals Co Ltd PYRIDYLTETRAHYDROPYRIDINE, PYRIDYLPIPERIDINE AND METHOD FOR THE PRODUCTION THEREOF
PT1699455E (pt) 2003-12-15 2013-08-27 Merck Sharp & Dohme Inibidores de protease de aspartilo heterocíclicos
JP2007532676A (ja) 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリジン
CN101495464B (zh) 2005-12-29 2014-03-05 詹森药业有限公司 激肽原1受体拮抗剂
CN101405002A (zh) 2005-12-29 2009-04-08 詹森药业有限公司 激肽原2受体拮抗剂
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
WO2008130718A1 (en) * 2007-04-23 2008-10-30 Atherogenics, Inc. Sulfonamide containing compounds for treatment of inflammatory disorders
WO2010077976A2 (en) 2008-12-17 2010-07-08 The Regents Of The University Of California Prokineticin receptor antagonists and uses thereof
US8436019B2 (en) * 2009-03-31 2013-05-07 Vanderbilt University Sulfonyl-piperidin-4-yl methylamine amide analogs as GlyT1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds

Also Published As

Publication number Publication date
AR091208A1 (es) 2015-01-21
HUE037673T2 (hu) 2018-09-28
CA2873850A1 (en) 2013-12-05
ME03078B (me) 2019-01-20
US20230073334A1 (en) 2023-03-09
HRP20180729T1 (hr) 2018-07-27
TW201400473A (zh) 2014-01-01
HK1208675A1 (en) 2016-03-11
WO2013179024A1 (en) 2013-12-05
SI2855449T1 (en) 2018-07-31
PL2855449T3 (pl) 2019-01-31
NO2855449T3 (pt) 2018-08-04
JP6177896B2 (ja) 2017-08-09
ES2671629T3 (es) 2018-06-07
US20200190059A1 (en) 2020-06-18
US10167273B2 (en) 2019-01-01
US20160376256A1 (en) 2016-12-29
US10544126B2 (en) 2020-01-28
US11512066B2 (en) 2022-11-29
US9475795B2 (en) 2016-10-25
CN104520292A (zh) 2015-04-15
JP2015519357A (ja) 2015-07-09
US20150111922A1 (en) 2015-04-23
CA2873850C (en) 2016-10-04
TWI612041B (zh) 2018-01-21
LT2855449T (lt) 2018-05-25
US20130324576A1 (en) 2013-12-05
CN104520292B (zh) 2016-09-14
RS57329B1 (sr) 2018-08-31
US20190084962A1 (en) 2019-03-21
EP2855449B1 (en) 2018-03-07
EP2855449A1 (en) 2015-04-08
CY1120420T1 (el) 2019-07-10
UY34835A (es) 2013-12-31
GB201209587D0 (en) 2012-07-11
DK2855449T3 (en) 2018-06-06
TR201807666T4 (tr) 2018-06-21

Similar Documents

Publication Publication Date Title
HRP20180729T1 (hr) Derivati sulfonil piperidina i njihova uporaba za liječenje bolesti posredovanih prokinetikinom
EP2914183A4 (en) SURGICAL INCISION AND CLOSURE APPARATUS
EP2895079A4 (en) DISPOSABLE CAPSULORHEXIS FORCEPS
EP2852352A4 (en) SURGICAL INSTRUMENTS AND METHOD FOR THEIR USE
DK2877184T3 (da) Sammensætninger og behandling for øjensygdomme og -lidelser
GB201223090D0 (en) Surgical forceps
IL245449A0 (en) Tissue skeletal materials for tissue regeneration and methods of preparation
IL229963A (en) Converted quinolines and their use as drugs
DK3292875T3 (en) Compositions and methods for treating diseases
PL2842945T3 (pl) Pochodna sulfonamidowa i jej zastosowanie medyczne
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
HK1200348A1 (en) Methods and materials for treatment of pompes disease
IL234606B (en) Innovative methods and compounds for the treatment of diseases
EP2931324A4 (en) COMPOSITIONS AND METHODS FOR TISSUE REGENERATION
HK1210941A1 (en) Modified hyaluronic acid derivatives and use thereof
EP2968452A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NETWORK DISEASES
EP2863939A4 (en) COMPOSITIONS AND METHODS FOR TREATING VITILIGO
EP2832724A4 (en) NIPETIC ACID DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
GB201219491D0 (en) Surgical controller
HK1209674A1 (en) Heterocyclyl carboxamides for treating viral diseases
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS
EP2830640A4 (en) METHODS AND COMPOSITIONS FOR TREATING ARTERIOSCLEROSTIC VASCULAR DISEASES
EP2988737A4 (en) Methods and compositions for treating diseases
EP2817004A4 (en) BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES
HK1205946A1 (en) Methods and compositions for treating arteriosclerotic vascular diseases